Drugs that contain Doravirine; Lamivudine; Tenofovir Disoproxil Fumarate
1. Delstrigo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8486975 | MSD MERCK CO | Non-nucleoside reverse transcriptase inhibitors |
Oct, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603282 | MSD MERCK CO | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
Nov, 2036
(12 years from now) | |
| US10842751 | MSD MERCK CO | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
Nov, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jan 27, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2023 |
| New Indication(I-806) | Sep 19, 2022 |
NCE-1 date: 30 August, 2022
Market Authorisation Date: 30 August, 2018
Treatment: Treatment of hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically...
Dosage: TABLET;ORAL
How can I launch a generic of DELSTRIGO before it's drug patent expiration?
More Information on Dosage
DELSTRIGO family patents
